GlassScriptPhysician profile
Jan W Madison
NPI 1275529760
$18,343.22
in general payments reported to CMS, 2019-2025
32 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $9,528 · 2021: $261 · 2022: $334 · 2023: $2,163 · 2024: $1,957 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,729 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,729.01 |
| Education | $227.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,088.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,433.74 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $828.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $495.09 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $446.73 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.31 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $394.18 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $367.28 | 2019 | |
| Philips North America LLC | $299.37 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Electromed, INC. | $206.74 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $198.34 | 2019 | |
| Pfizer INC. | $129.81 | 2019-2025 | |
| Harmony Biosciences LLC | $124.88 | 2023-2025 | Wakix |
| Insmed, INC. | $116.56 | 2019-2025 | Arikayce |
| Inspire Medical Systems, INC. | $108.93 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100.62 | 2019-2025 | Zerbaxa |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| United Therapeutics Corporation | $71.87 | 2024 | Tyvaso |
| Shire North American Group INC | $53.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.14 | 2023-2024 | Glassia |
| Gilead Sciences, INC. | $38.35 | 2019 | |
| Baxter Healthcare | $37.72 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $37.62 | 2025 | Ohtuvayre |
| Inogen, INC. | $34.70 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols Shared Services North America, INC. | $30.00 | 2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $29.87 | 2024 | Terlivaz |
| Vifor Pharma, INC. | $23.36 | 2024 | Zemaira |
| Vapotherm INC | $19.80 | 2024 | Vapotherm |
| Advanced Respiratory, INC | $16.94 | 2019 | |
| Csl Behring | $16.11 | 2020 | |
| Pulmonx Corporation | $14.59 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Abbvie INC. | $14.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Madison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.